Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Pfizer shows promise. The company has positioned itself for growth in oncology, including a $43 billion acquisition of Seagen to boost its pipeline. Plus, Pfizer could enter the hot GLP-1 agonist ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...